{ "ok": true, "doi": "10.46243/jst.2022.v7.i05.pp179-184", "events": [ { "seq": 1, "kind": "register", "at": "2026-09-29 22:00:27", "by": "Administrator (admin)", "by_kind": "user", "note": "registered at Crossref; record read from api.crossref.org", "changes": [ { "path": "abstract.lang", "from": null, "to": "en" }, { "path": "abstract.value", "from": null, "to": "This study aimed to analyze the association of the CYP2C9*2 variant of the CYP2C9 family with hyperhomocysteinemia in cardiovascular patients. To carry out the research, genomic DNA was extracted from 100 hyperhomocysteinemic blood samples collected from KRL General Hospital and 40 control blood samples. Polymerase chain reaction and RFLP were performed on the selected hyperhomocysteinemic samples using AvaII restriction enzyme, and the results were analyzed on a gel documentation system. Among the three possible genotypes, CC, CT, and TT, only CC and CT were found in the study, with TT showing a frequency of zero. The calculated P value was 0.924, which was greater than the standard P value of 0.05, and the body mass index was found to be a major risk factor associated with cardiovascular diseases with a mean body mass index of 36.39. The allelic frequency of C was 0.86% and the frequency of the T allele was 0.13% in hyperhomocysteinemic patients. The findings conclude that there is no significant association between the CYP2C9*2 variant and elevated homocysteine levels in patients with cardiovascular diseases in the selected population." }, { "path": "agents.0.name.family", "from": null, "to": "Mehak Maryyam" }, { "path": "agents.0.name.given", "from": null, "to": "Mehak Maryyam" }, { "path": "agents.0.role", "from": null, "to": "author" }, { "path": "agents.0.sequence", "from": null, "to": "first" }, { "path": "agents.1.name.org", "from": null, "to": "Longman Publishers" }, { "path": "agents.1.role", "from": null, "to": "publisher" }, { "path": "characters.0", "from": null, "to": "Language" }, { "path": "container.identifiers.0.medium", "from": null, "to": "electronic" }, { "path": "container.identifiers.0.type", "from": null, "to": "ISSN" }, { "path": "container.identifiers.0.value", "from": null, "to": "2456-5660" }, { "path": "container.issue", "from": null, "to": "5" }, { "path": "container.pages.first", "from": null, "to": "179" }, { "path": "container.pages.last", "from": null, "to": "184" }, { "path": "container.titles.0.type", "from": null, "to": "PrincipalTitle" }, { "path": "container.titles.0.value", "from": null, "to": "Journal of Science & Technology" }, { "path": "container.type", "from": null, "to": "Journal" }, { "path": "container.volume", "from": null, "to": "7" }, { "path": "dates.date_type", "from": null, "to": "PublicationDate" }, { "path": "dates.online", "from": null, "to": "2023-07-18" }, { "path": "dates.published", "from": null, "to": "2023-07-18" }, { "path": "doi", "from": null, "to": "10.46243/jst.2022.v7.i05.pp179-184" }, { "path": "format", "from": null, "to": "smartscholars-doi-metadata/1.0" }, { "path": "identifiers.0.type", "from": null, "to": "DOI" }, { "path": "identifiers.0.value", "from": null, "to": "10.46243/jst.2022.v7.i05.pp179-184" }, { "path": "language", "from": null, "to": "en" }, { "path": "license.applies_to", "from": null, "to": "vor" }, { "path": "license.start", "from": null, "to": "2023-07-18" }, { "path": "license.url", "from": null, "to": "https://creativecommons.org/licenses/by/4.0/" }, { "path": "links.0.primary", "from": null, "to": true }, { "path": "links.0.return_type", "from": null, "to": "text/html" }, { "path": "links.0.url", "from": null, "to": "https://www.jst.org.in/index.php/pub/article/view/529" }, { "path": "links.1.purpose", "from": null, "to": "text-mining" }, { "path": "links.1.return_type", "from": null, "to": "application/pdf" }, { "path": "links.1.url", "from": null, "to": "https://www.jst.org.in/index.php/pub/article/download/529/475" }, { "path": "links.2.purpose", "from": null, "to": "text-mining" }, { "path": "links.2.return_type", "from": null, "to": "application/xml" }, { "path": "links.2.url", "from": null, "to": "https://www.jst.org.in/index.php/pub/article/download/529/2063" }, { "path": "links.3.purpose", "from": null, "to": "similarity-checking" }, { "path": "links.3.url", "from": null, "to": "https://jst.org.in/admin/uploads/JST070512.pdf" }, { "path": "modes.0", "from": null, "to": "Visual" }, { "path": "record.issue_number", "from": null, "to": 1 }, { "path": "record.registered", "from": null, "to": "2024-02-16" }, { "path": "record.registrant", "from": null, "to": "Longman Publishers" }, { "path": "record.source", "from": null, "to": "crossref-api" }, { "path": "record.source_agency", "from": null, "to": "Crossref (member 25296)" }, { "path": "record.updated", "from": null, "to": "2026-09-20" }, { "path": "references.0.key", "from": null, "to": "ref1" }, { "path": "references.0.unstructured", "from": null, "to": "2. McKusick V. Homocystinuria due to deficiency of N (5,10)- methylene tetra hydro folate reductase activity. In: McKusick V, editor. Mendelian Inheritance in Man. Baltimore, MD: The Johns Hopkins University Press. 1992: 1447–1448" }, { "path": "references.1.doi", "from": null, "to": "10.4065/83.11.1203" }, { "path": "references.1.key", "from": null, "to": "ref2" }, { "path": "references.1.unstructured", "from": null, "to": "Humphrey LL, Fu R, Rogers K, Freeman M, Helfand M. Homocysteine level and coronary heart disease incidence: a systematic review and meta-analysis. Mayo ClinProc. 2008; 83:1203–1212" }, { "path": "references.10.doi", "from": null, "to": "10.1097/00008571-200004000-00001" }, { "path": "references.10.key", "from": null, "to": "ref11" }, { "path": "references.10.unstructured", "from": null, "to": "Streetman DS, Bertino JS, Nafziger AN. Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes. Pharmacogenetics. 2000; 10(3):187–216" }, { "path": "references.11.doi", "from": null, "to": "10.1515/cclm.2004.014" }, { "path": "references.11.key", "from": null, "to": "ref12" }, { "path": "references.11.unstructured", "from": null, "to": "Topic E, Stefanovic M, Samardzija M. Association between the CYP2C9 polymorphism and the drug metabolism phenotype. ClinChem Lab Med. 2004; 42(1):72–8" }, { "path": "references.12.doi", "from": null, "to": "10.1124/dmd.109.027003" }, { "path": "references.12.key", "from": null, "to": "ref13" }, { "path": "references.12.unstructured", "from": null, "to": "Maekawa K, Harakawa N, Sugiyama E, Tohkin M, Kim SR, Kaniwa N. Substrate-dependent Functional Alternations of Seven CYP2C9 Variants Found in Japanese Subjects. Drug Metabolism and Disposition. 2009; 1895-903" }, { "path": "references.13.doi", "from": null, "to": "10.1097/01.fpc.0000114749.08559.e4" }, { "path": "references.13.key", "from": null, "to": "ref14" }, { "path": "references.13.unstructured", "from": null, "to": "Si D, Guo Y, Zhang Y, Yang L, Zhou H, Zhong D. Identification of a Noval Variant CYP2C9 Allele in Chinese. Pharmacogenetics. 2004; 465-469" }, { "path": "references.14.doi", "from": null, "to": "10.1016/s0140-6736(98)04474-2" }, { "path": "references.14.key", "from": null, "to": "ref15" }, { "path": "references.14.unstructured", "from": null, "to": "Aithal GP, Day CP, Kesteven PJ, Daly AK. Association of Polymorphisms in the Cytochrome P450 CYP2C9 with Warfarin Dose Requirement and Risk of Bleeding Complications. Lancet, Vol. 353, No. 9154, 1999, pp. 717-719. doi: 10.1016/s0140- 6736(98)04474-2" }, { "path": "references.15.key", "from": null, "to": "ref16" }, { "path": "references.15.unstructured", "from": null, "to": "Schwarz UI, Clinical Relevance of Genetic Polymorphism in the Human CYP2C9 Gene. European Journal of Clinical Pharmacology. 2001; 277-280" }, { "path": "references.16.doi", "from": null, "to": "10.1097/fpc.0b013e32831ebb30" }, { "path": "references.16.key", "from": null, "to": "ref17" }, { "path": "references.16.unstructured", "from": null, "to": "Sistonen J, Fuselli S, Palo JU, Chauhan NH, Sajantila A, Pharmacogenetics variation at CYP2C9, CYP2C19, and CYP2D6 at global and micro geographic scales. Pharmacogenetics and genomics. 2009;19(2):170–9" }, { "path": "references.17.doi", "from": null, "to": "10.1517/14622416.5.7.895" }, { "path": "references.17.key", "from": null, "to": "ref18" }, { "path": "references.17.unstructured", "from": null, "to": "Solus JF, Arietta BJ, Harris JR, Sexton DP, Genetic variation in eleven phase I drug metabolism genes in an ethnically diverse population. Pharmacogenomics. 2004;5(7):895–931" }, { "path": "references.18.doi", "from": null, "to": "10.1097/00008571-200204000-00010" }, { "path": "references.18.key", "from": null, "to": "ref19" }, { "path": "references.18.unstructured", "from": null, "to": "Lee CR, Goldstein JA, Pieper JA, Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. Pharmacogenetics. 2002;12(3):251–63" }, { "path": "references.19.doi", "from": null, "to": "10.1093/eurheartj/ehq321" }, { "path": "references.19.key", "from": null, "to": "ref20" }, { "path": "references.19.unstructured", "from": null, "to": "Harmsze AM, Jochem W, Werkum V, Jurrie M, Berg T, Zwart B, Heleen J, Bouman NJ, Arnoud WJ, Hof V, Hendrik JT, Hackeng CM, Olaf H, Boer AD, Vera HM. CYP2C9*2 and CYP2C9*3 alleles are associated with stent thrombosis: a case control study. European Heart Journal. 2010; 3046-3053" }, { "path": "references.2.doi", "from": null, "to": "10.1023/a:1005325326802" }, { "path": "references.2.key", "from": null, "to": "ref3" }, { "path": "references.2.unstructured", "from": null, "to": "Boers GH. The case for mild hyperhomocysteinaemia as a risk factor. J Inherit Metab Dis 1997; 20:301–306" }, { "path": "references.20.doi", "from": null, "to": "10.1046/j.1365-2125.2001.00340.x" }, { "path": "references.20.key", "from": null, "to": "ref21" }, { "path": "references.20.unstructured", "from": null, "to": "23.Yoon YR, Shon JH, Kim MK, Lim YC, Lee HR, Park JY, Cha IJ, Shin JG. Frequency of cytochrome P450 2C9 mutant alleles in a Korean population. Br. J. Clin. Pharmacol. 2001; 277–280 Table 1: Mean values for the characteristics of HHC Table 2: Frequency of Parameters Table 3: Genotype Distribution of CC, CT and TT for CYP2C9*2 in HHC Patients and Controls Table 4: Chi-Square and P-value Calculated Using SPSS Version 16.0 Table 5: Mean BMI of HHC Patients in Effect of CYP2C9*2" }, { "path": "references.3.doi", "from": null, "to": "10.1038/sj.cdd.4401451" }, { "path": "references.3.key", "from": null, "to": "ref4" }, { "path": "references.3.unstructured", "from": null, "to": "Austin RC, Lentz SR, Werstuck GH. Role of Hyperhomocystenemia in endothelial dysfunction and atherothrombotic disease. Cell Death Differ 2004; 11(suppl 1):S56–S64" }, { "path": "references.4.doi", "from": null, "to": "10.1126/science.234.4778.884.a" }, { "path": "references.4.key", "from": null, "to": "ref5" }, { "path": "references.4.unstructured", "from": null, "to": "Ortiz de Montellano, PR. “Cytochrome P-450: Structure, Mechanism and Biochemistry,” Plenum, New York and London" }, { "path": "references.5.doi", "from": null, "to": "10.1089/dna.1991.10.1" }, { "path": "references.5.key", "from": null, "to": "ref6" }, { "path": "references.5.unstructured", "from": null, "to": "Nebert DW, Nelson DR, Minor JC, Estabrook, RW, Feyereisen, R, Fuji-Kuriyama, Y, Gonzalez FJ, Guengerich FP, Gunsalus IC, Johnson EF, loper JC, Stato R, Waterman MR, Waxman DJ. The P450 superfamily: Update on new sequences, gene mapping, and recommended nomenclature. DNA Cell Biol. 1991; 10:1-14" }, { "path": "references.6.doi", "from": null, "to": "10.1097/00008571-199602000-00002" }, { "path": "references.6.key", "from": null, "to": "ref7" }, { "path": "references.6.unstructured", "from": null, "to": "Nelson D.R., Koymans L, Kamataki T, Stegeman JJ, Feyereisen R, Waxman DJ, Waterman MR, Gotoh O, Coon MJ, Estabrook, RW Gunsalus IC, Nebert DW. P450 superfamily: update on new sequences, gene mapping,accession numbers and nomenclature. Pharmacogenetics 6. 1996; 1–42.7" }, { "path": "references.7.doi", "from": null, "to": "10.1006/geno.1995.1149" }, { "path": "references.7.key", "from": null, "to": "ref8" }, { "path": "references.7.unstructured", "from": null, "to": "Gray IC, Nobile C, Muresu R, Ford S, Spurr NK. A 2.4-megabase physical map spanning the CYP2C gene cluster on chromosome 10q24. Genomics. 1995; 328–332" }, { "path": "references.8.doi", "from": null, "to": "10.1006/bbrc.1993.1803" }, { "path": "references.8.key", "from": null, "to": "ref9" }, { "path": "references.8.unstructured", "from": null, "to": "Morais SMF, Schweiki H, Blaisdell J, Goldstein JA. Gene structure and upstream regulatory regions of human CYP2C9 and CYP2C18. Biochem. Biophys. Res. Commun. 1993; 194–201" }, { "path": "references.9.doi", "from": null, "to": "10.1097/00008571-199412000-00001" }, { "path": "references.9.key", "from": null, "to": "ref10" }, { "path": "references.9.unstructured", "from": null, "to": "Goldstein JA, de Morais SM. Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics. 1994; 6:285–99" }, { "path": "referent", "from": null, "to": "Creation" }, { "path": "structural_type", "from": null, "to": "Digital" }, { "path": "titles.0.lang", "from": null, "to": "en" }, { "path": "titles.0.type", "from": null, "to": "PrincipalTitle" }, { "path": "titles.0.value", "from": null, "to": "Molecular Screening & Influence of Cyp2C9*2 Variant with HHC in CVD Patients" }, { "path": "type", "from": null, "to": "JournalArticle" } ], "record_after": { "format": "smartscholars-doi-metadata/1.0", "doi": "10.46243/jst.2022.v7.i05.pp179-184", "referent": "Creation", "type": "JournalArticle", "structural_type": "Digital", "modes": [ "Visual" ], "characters": [ "Language" ], "titles": [ { "value": "Molecular Screening & Influence of Cyp2C9*2 Variant with HHC in CVD Patients", "type": "PrincipalTitle", "lang": "en" } ], "identifiers": [ { "type": "DOI", "value": "10.46243/jst.2022.v7.i05.pp179-184" } ], "agents": [ { "role": "author", "name": { "given": "Mehak Maryyam", "family": "Mehak Maryyam" }, "sequence": "first" }, { "role": "publisher", "name": { "org": "Longman Publishers" } } ], "dates": { "published": "2023-07-18", "date_type": "PublicationDate", "online": "2023-07-18" }, "language": "en", "container": { "type": "Journal", "titles": [ { "value": "Journal of Science & Technology", "type": "PrincipalTitle" } ], "identifiers": [ { "type": "ISSN", "value": "2456-5660", "medium": "electronic" } ], "volume": "7", "issue": "5", "pages": { "first": "179", "last": "184" } }, "links": [ { "url": "https://www.jst.org.in/index.php/pub/article/view/529", "return_type": "text/html", "primary": true }, { "url": "https://www.jst.org.in/index.php/pub/article/download/529/475", "purpose": "text-mining", "return_type": "application/pdf" }, { "url": "https://www.jst.org.in/index.php/pub/article/download/529/2063", "purpose": "text-mining", "return_type": "application/xml" }, { "url": "https://jst.org.in/admin/uploads/JST070512.pdf", "purpose": "similarity-checking" } ], "abstract": { "value": "This study aimed to analyze the association of the CYP2C9*2 variant of the CYP2C9 family with hyperhomocysteinemia in cardiovascular patients. To carry out the research, genomic DNA was extracted from 100 hyperhomocysteinemic blood samples collected from KRL General Hospital and 40 control blood samples. Polymerase chain reaction and RFLP were performed on the selected hyperhomocysteinemic samples using AvaII restriction enzyme, and the results were analyzed on a gel documentation system. Among the three possible genotypes, CC, CT, and TT, only CC and CT were found in the study, with TT showing a frequency of zero. The calculated P value was 0.924, which was greater than the standard P value of 0.05, and the body mass index was found to be a major risk factor associated with cardiovascular diseases with a mean body mass index of 36.39. The allelic frequency of C was 0.86% and the frequency of the T allele was 0.13% in hyperhomocysteinemic patients. The findings conclude that there is no significant association between the CYP2C9*2 variant and elevated homocysteine levels in patients with cardiovascular diseases in the selected population.", "lang": "en" }, "license": { "url": "https://creativecommons.org/licenses/by/4.0/", "start": "2023-07-18", "applies_to": "vor" }, "references": [ { "key": "ref1", "unstructured": "2. McKusick V. Homocystinuria due to deficiency of N (5,10)- methylene tetra hydro folate reductase activity. In: McKusick V, editor. Mendelian Inheritance in Man. Baltimore, MD: The Johns Hopkins University Press. 1992: 1447–1448" }, { "key": "ref2", "doi": "10.4065/83.11.1203", "unstructured": "Humphrey LL, Fu R, Rogers K, Freeman M, Helfand M. Homocysteine level and coronary heart disease incidence: a systematic review and meta-analysis. Mayo ClinProc. 2008; 83:1203–1212" }, { "key": "ref3", "doi": "10.1023/a:1005325326802", "unstructured": "Boers GH. The case for mild hyperhomocysteinaemia as a risk factor. J Inherit Metab Dis 1997; 20:301–306" }, { "key": "ref4", "doi": "10.1038/sj.cdd.4401451", "unstructured": "Austin RC, Lentz SR, Werstuck GH. Role of Hyperhomocystenemia in endothelial dysfunction and atherothrombotic disease. Cell Death Differ 2004; 11(suppl 1):S56–S64" }, { "key": "ref5", "doi": "10.1126/science.234.4778.884.a", "unstructured": "Ortiz de Montellano, PR. “Cytochrome P-450: Structure, Mechanism and Biochemistry,” Plenum, New York and London" }, { "key": "ref6", "doi": "10.1089/dna.1991.10.1", "unstructured": "Nebert DW, Nelson DR, Minor JC, Estabrook, RW, Feyereisen, R, Fuji-Kuriyama, Y, Gonzalez FJ, Guengerich FP, Gunsalus IC, Johnson EF, loper JC, Stato R, Waterman MR, Waxman DJ. The P450 superfamily: Update on new sequences, gene mapping, and recommended nomenclature. DNA Cell Biol. 1991; 10:1-14" }, { "key": "ref7", "doi": "10.1097/00008571-199602000-00002", "unstructured": "Nelson D.R., Koymans L, Kamataki T, Stegeman JJ, Feyereisen R, Waxman DJ, Waterman MR, Gotoh O, Coon MJ, Estabrook, RW Gunsalus IC, Nebert DW. P450 superfamily: update on new sequences, gene mapping,accession numbers and nomenclature. Pharmacogenetics 6. 1996; 1–42.7" }, { "key": "ref8", "doi": "10.1006/geno.1995.1149", "unstructured": "Gray IC, Nobile C, Muresu R, Ford S, Spurr NK. A 2.4-megabase physical map spanning the CYP2C gene cluster on chromosome 10q24. Genomics. 1995; 328–332" }, { "key": "ref9", "doi": "10.1006/bbrc.1993.1803", "unstructured": "Morais SMF, Schweiki H, Blaisdell J, Goldstein JA. Gene structure and upstream regulatory regions of human CYP2C9 and CYP2C18. Biochem. Biophys. Res. Commun. 1993; 194–201" }, { "key": "ref10", "doi": "10.1097/00008571-199412000-00001", "unstructured": "Goldstein JA, de Morais SM. Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics. 1994; 6:285–99" }, { "key": "ref11", "doi": "10.1097/00008571-200004000-00001", "unstructured": "Streetman DS, Bertino JS, Nafziger AN. Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes. Pharmacogenetics. 2000; 10(3):187–216" }, { "key": "ref12", "doi": "10.1515/cclm.2004.014", "unstructured": "Topic E, Stefanovic M, Samardzija M. Association between the CYP2C9 polymorphism and the drug metabolism phenotype. ClinChem Lab Med. 2004; 42(1):72–8" }, { "key": "ref13", "doi": "10.1124/dmd.109.027003", "unstructured": "Maekawa K, Harakawa N, Sugiyama E, Tohkin M, Kim SR, Kaniwa N. Substrate-dependent Functional Alternations of Seven CYP2C9 Variants Found in Japanese Subjects. Drug Metabolism and Disposition. 2009; 1895-903" }, { "key": "ref14", "doi": "10.1097/01.fpc.0000114749.08559.e4", "unstructured": "Si D, Guo Y, Zhang Y, Yang L, Zhou H, Zhong D. Identification of a Noval Variant CYP2C9 Allele in Chinese. Pharmacogenetics. 2004; 465-469" }, { "key": "ref15", "doi": "10.1016/s0140-6736(98)04474-2", "unstructured": "Aithal GP, Day CP, Kesteven PJ, Daly AK. Association of Polymorphisms in the Cytochrome P450 CYP2C9 with Warfarin Dose Requirement and Risk of Bleeding Complications. Lancet, Vol. 353, No. 9154, 1999, pp. 717-719. doi: 10.1016/s0140- 6736(98)04474-2" }, { "key": "ref16", "unstructured": "Schwarz UI, Clinical Relevance of Genetic Polymorphism in the Human CYP2C9 Gene. European Journal of Clinical Pharmacology. 2001; 277-280" }, { "key": "ref17", "doi": "10.1097/fpc.0b013e32831ebb30", "unstructured": "Sistonen J, Fuselli S, Palo JU, Chauhan NH, Sajantila A, Pharmacogenetics variation at CYP2C9, CYP2C19, and CYP2D6 at global and micro geographic scales. Pharmacogenetics and genomics. 2009;19(2):170–9" }, { "key": "ref18", "doi": "10.1517/14622416.5.7.895", "unstructured": "Solus JF, Arietta BJ, Harris JR, Sexton DP, Genetic variation in eleven phase I drug metabolism genes in an ethnically diverse population. Pharmacogenomics. 2004;5(7):895–931" }, { "key": "ref19", "doi": "10.1097/00008571-200204000-00010", "unstructured": "Lee CR, Goldstein JA, Pieper JA, Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. Pharmacogenetics. 2002;12(3):251–63" }, { "key": "ref20", "doi": "10.1093/eurheartj/ehq321", "unstructured": "Harmsze AM, Jochem W, Werkum V, Jurrie M, Berg T, Zwart B, Heleen J, Bouman NJ, Arnoud WJ, Hof V, Hendrik JT, Hackeng CM, Olaf H, Boer AD, Vera HM. CYP2C9*2 and CYP2C9*3 alleles are associated with stent thrombosis: a case control study. European Heart Journal. 2010; 3046-3053" }, { "key": "ref21", "doi": "10.1046/j.1365-2125.2001.00340.x", "unstructured": "23.Yoon YR, Shon JH, Kim MK, Lim YC, Lee HR, Park JY, Cha IJ, Shin JG. Frequency of cytochrome P450 2C9 mutant alleles in a Korean population. Br. J. Clin. Pharmacol. 2001; 277–280 Table 1: Mean values for the characteristics of HHC Table 2: Frequency of Parameters Table 3: Genotype Distribution of CC, CT and TT for CYP2C9*2 in HHC Patients and Controls Table 4: Chi-Square and P-value Calculated Using SPSS Version 16.0 Table 5: Mean BMI of HHC Patients in Effect of CYP2C9*2" } ], "record": { "registrant": "Longman Publishers", "registered": "2024-02-16", "updated": "2026-09-20", "issue_number": 1, "source": "crossref-api", "source_agency": "Crossref (member 25296)" } }, "url_after": "https://www.jst.org.in/index.php/pub/article/view/529", "sha256_before": null, "sha256_after": "9a86038bac4a816424c3632f54916e32feec74e00b0deedc8da252e8bea8c08c" }, { "seq": 2, "kind": "update", "at": "2026-09-29 23:59:46", "by": "Administrator (admin)", "by_kind": "user", "note": "record re-read from api.crossref.org", "changes": [ { "path": "container.titles.0.value", "from": "Journal of Science & Technology", "to": "Journal of Science & Technology" }, { "path": "titles.0.value", "from": "Molecular Screening & Influence of Cyp2C9*2 Variant with HHC in CVD Patients", "to": "Molecular Screening & Influence of Cyp2C9*2 Variant with HHC in CVD Patients" } ], "record_after": { "format": "smartscholars-doi-metadata/1.0", "doi": "10.46243/jst.2022.v7.i05.pp179-184", "referent": "Creation", "type": "JournalArticle", "structural_type": "Digital", "modes": [ "Visual" ], "characters": [ "Language" ], "titles": [ { "value": "Molecular Screening & Influence of Cyp2C9*2 Variant with HHC in CVD Patients", "type": "PrincipalTitle", "lang": "en" } ], "identifiers": [ { "type": "DOI", "value": "10.46243/jst.2022.v7.i05.pp179-184" } ], "agents": [ { "role": "author", "name": { "given": "Mehak Maryyam", "family": "Mehak Maryyam" }, "sequence": "first" }, { "role": "publisher", "name": { "org": "Longman Publishers" } } ], "dates": { "published": "2023-07-18", "date_type": "PublicationDate", "online": "2023-07-18" }, "language": "en", "container": { "type": "Journal", "titles": [ { "value": "Journal of Science & Technology", "type": "PrincipalTitle" } ], "identifiers": [ { "type": "ISSN", "value": "2456-5660", "medium": "electronic" } ], "volume": "7", "issue": "5", "pages": { "first": "179", "last": "184" } }, "links": [ { "url": "https://www.jst.org.in/index.php/pub/article/view/529", "return_type": "text/html", "primary": true }, { "url": "https://www.jst.org.in/index.php/pub/article/download/529/475", "purpose": "text-mining", "return_type": "application/pdf" }, { "url": "https://www.jst.org.in/index.php/pub/article/download/529/2063", "purpose": "text-mining", "return_type": "application/xml" }, { "url": "https://jst.org.in/admin/uploads/JST070512.pdf", "purpose": "similarity-checking" } ], "abstract": { "value": "This study aimed to analyze the association of the CYP2C9*2 variant of the CYP2C9 family with hyperhomocysteinemia in cardiovascular patients. To carry out the research, genomic DNA was extracted from 100 hyperhomocysteinemic blood samples collected from KRL General Hospital and 40 control blood samples. Polymerase chain reaction and RFLP were performed on the selected hyperhomocysteinemic samples using AvaII restriction enzyme, and the results were analyzed on a gel documentation system. Among the three possible genotypes, CC, CT, and TT, only CC and CT were found in the study, with TT showing a frequency of zero. The calculated P value was 0.924, which was greater than the standard P value of 0.05, and the body mass index was found to be a major risk factor associated with cardiovascular diseases with a mean body mass index of 36.39. The allelic frequency of C was 0.86% and the frequency of the T allele was 0.13% in hyperhomocysteinemic patients. The findings conclude that there is no significant association between the CYP2C9*2 variant and elevated homocysteine levels in patients with cardiovascular diseases in the selected population.", "lang": "en" }, "license": { "url": "https://creativecommons.org/licenses/by/4.0/", "start": "2023-07-18", "applies_to": "vor" }, "references": [ { "key": "ref1", "unstructured": "2. McKusick V. Homocystinuria due to deficiency of N (5,10)- methylene tetra hydro folate reductase activity. In: McKusick V, editor. Mendelian Inheritance in Man. Baltimore, MD: The Johns Hopkins University Press. 1992: 1447–1448" }, { "key": "ref2", "doi": "10.4065/83.11.1203", "unstructured": "Humphrey LL, Fu R, Rogers K, Freeman M, Helfand M. Homocysteine level and coronary heart disease incidence: a systematic review and meta-analysis. Mayo ClinProc. 2008; 83:1203–1212" }, { "key": "ref3", "doi": "10.1023/a:1005325326802", "unstructured": "Boers GH. The case for mild hyperhomocysteinaemia as a risk factor. J Inherit Metab Dis 1997; 20:301–306" }, { "key": "ref4", "doi": "10.1038/sj.cdd.4401451", "unstructured": "Austin RC, Lentz SR, Werstuck GH. Role of Hyperhomocystenemia in endothelial dysfunction and atherothrombotic disease. Cell Death Differ 2004; 11(suppl 1):S56–S64" }, { "key": "ref5", "doi": "10.1126/science.234.4778.884.a", "unstructured": "Ortiz de Montellano, PR. “Cytochrome P-450: Structure, Mechanism and Biochemistry,” Plenum, New York and London" }, { "key": "ref6", "doi": "10.1089/dna.1991.10.1", "unstructured": "Nebert DW, Nelson DR, Minor JC, Estabrook, RW, Feyereisen, R, Fuji-Kuriyama, Y, Gonzalez FJ, Guengerich FP, Gunsalus IC, Johnson EF, loper JC, Stato R, Waterman MR, Waxman DJ. The P450 superfamily: Update on new sequences, gene mapping, and recommended nomenclature. DNA Cell Biol. 1991; 10:1-14" }, { "key": "ref7", "doi": "10.1097/00008571-199602000-00002", "unstructured": "Nelson D.R., Koymans L, Kamataki T, Stegeman JJ, Feyereisen R, Waxman DJ, Waterman MR, Gotoh O, Coon MJ, Estabrook, RW Gunsalus IC, Nebert DW. P450 superfamily: update on new sequences, gene mapping,accession numbers and nomenclature. Pharmacogenetics 6. 1996; 1–42.7" }, { "key": "ref8", "doi": "10.1006/geno.1995.1149", "unstructured": "Gray IC, Nobile C, Muresu R, Ford S, Spurr NK. A 2.4-megabase physical map spanning the CYP2C gene cluster on chromosome 10q24. Genomics. 1995; 328–332" }, { "key": "ref9", "doi": "10.1006/bbrc.1993.1803", "unstructured": "Morais SMF, Schweiki H, Blaisdell J, Goldstein JA. Gene structure and upstream regulatory regions of human CYP2C9 and CYP2C18. Biochem. Biophys. Res. Commun. 1993; 194–201" }, { "key": "ref10", "doi": "10.1097/00008571-199412000-00001", "unstructured": "Goldstein JA, de Morais SM. Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics. 1994; 6:285–99" }, { "key": "ref11", "doi": "10.1097/00008571-200004000-00001", "unstructured": "Streetman DS, Bertino JS, Nafziger AN. Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes. Pharmacogenetics. 2000; 10(3):187–216" }, { "key": "ref12", "doi": "10.1515/cclm.2004.014", "unstructured": "Topic E, Stefanovic M, Samardzija M. Association between the CYP2C9 polymorphism and the drug metabolism phenotype. ClinChem Lab Med. 2004; 42(1):72–8" }, { "key": "ref13", "doi": "10.1124/dmd.109.027003", "unstructured": "Maekawa K, Harakawa N, Sugiyama E, Tohkin M, Kim SR, Kaniwa N. Substrate-dependent Functional Alternations of Seven CYP2C9 Variants Found in Japanese Subjects. Drug Metabolism and Disposition. 2009; 1895-903" }, { "key": "ref14", "doi": "10.1097/01.fpc.0000114749.08559.e4", "unstructured": "Si D, Guo Y, Zhang Y, Yang L, Zhou H, Zhong D. Identification of a Noval Variant CYP2C9 Allele in Chinese. Pharmacogenetics. 2004; 465-469" }, { "key": "ref15", "doi": "10.1016/s0140-6736(98)04474-2", "unstructured": "Aithal GP, Day CP, Kesteven PJ, Daly AK. Association of Polymorphisms in the Cytochrome P450 CYP2C9 with Warfarin Dose Requirement and Risk of Bleeding Complications. Lancet, Vol. 353, No. 9154, 1999, pp. 717-719. doi: 10.1016/s0140- 6736(98)04474-2" }, { "key": "ref16", "unstructured": "Schwarz UI, Clinical Relevance of Genetic Polymorphism in the Human CYP2C9 Gene. European Journal of Clinical Pharmacology. 2001; 277-280" }, { "key": "ref17", "doi": "10.1097/fpc.0b013e32831ebb30", "unstructured": "Sistonen J, Fuselli S, Palo JU, Chauhan NH, Sajantila A, Pharmacogenetics variation at CYP2C9, CYP2C19, and CYP2D6 at global and micro geographic scales. Pharmacogenetics and genomics. 2009;19(2):170–9" }, { "key": "ref18", "doi": "10.1517/14622416.5.7.895", "unstructured": "Solus JF, Arietta BJ, Harris JR, Sexton DP, Genetic variation in eleven phase I drug metabolism genes in an ethnically diverse population. Pharmacogenomics. 2004;5(7):895–931" }, { "key": "ref19", "doi": "10.1097/00008571-200204000-00010", "unstructured": "Lee CR, Goldstein JA, Pieper JA, Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. Pharmacogenetics. 2002;12(3):251–63" }, { "key": "ref20", "doi": "10.1093/eurheartj/ehq321", "unstructured": "Harmsze AM, Jochem W, Werkum V, Jurrie M, Berg T, Zwart B, Heleen J, Bouman NJ, Arnoud WJ, Hof V, Hendrik JT, Hackeng CM, Olaf H, Boer AD, Vera HM. CYP2C9*2 and CYP2C9*3 alleles are associated with stent thrombosis: a case control study. European Heart Journal. 2010; 3046-3053" }, { "key": "ref21", "doi": "10.1046/j.1365-2125.2001.00340.x", "unstructured": "23.Yoon YR, Shon JH, Kim MK, Lim YC, Lee HR, Park JY, Cha IJ, Shin JG. Frequency of cytochrome P450 2C9 mutant alleles in a Korean population. Br. J. Clin. Pharmacol. 2001; 277–280 Table 1: Mean values for the characteristics of HHC Table 2: Frequency of Parameters Table 3: Genotype Distribution of CC, CT and TT for CYP2C9*2 in HHC Patients and Controls Table 4: Chi-Square and P-value Calculated Using SPSS Version 16.0 Table 5: Mean BMI of HHC Patients in Effect of CYP2C9*2" } ], "record": { "registrant": "Longman Publishers", "registered": "2024-02-16", "updated": "2026-09-20", "issue_number": 1, "source": "crossref-api", "source_agency": "Crossref (member 25296)" } }, "url_after": "https://www.jst.org.in/index.php/pub/article/view/529", "sha256_before": "9a86038bac4a816424c3632f54916e32feec74e00b0deedc8da252e8bea8c08c", "sha256_after": "edad7f3dcba64edcbe07c48bca4d10ae443fc6a08caaa36336eb352b121aa738" } ] }